Welsh School of Pharmacy

Peer reviewed articles (Since 2001)

Morgan L., Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis, I, Kawakatsu H, Nicholson R, Hiscox S. (2009). Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Can Biol Therapy. 8(16)

Hiscox S, Lloyd Davies E, Barrett-Lee P (2009). Aromatase inhibitors in breast cancer. Maturitas 63:275-279

Hiscox S, Morgan L, Jordan N, Gee J, Nicholson RI (2009). Targeting Adverse Features of Hormone-Resistant Breast Cancer: Acquired Endocrine Resistance in Breast Cancer. In: Drug resistant neoplasms, Nova Science Publishers, Inc. Ed: Ethan G. Verrite. In press

Borley A, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI. (2008). Antioestrogens but not oestrogen deprivation promote cellular invasion in intercellular-adhesion deficient breast cancer cells. Breast Cancer Research In press

Hiscox S, Jordan N, Smith C, James M, Green T, Nicholson RI. (2008). Dual targeting of Src and the ER prevents acquired tamoxifen resistance in breast cancer cells. Breast Cancer Res Treat. May 21. [Epub ahead of print]

Hiscox S and Nicholson RI. (2008). Src inhibitors in breast cancer therapy. Expert Opin Ther Targets 12(6):757-767.

Morgan L, Nicholson RI and Hiscox S. (2008). Src as a therapeutic target in breast cancer. Endocrine, Metabolic & Immune Disorders - Drug Targets. In press

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor K and Gee JWM. (2007). Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord. 2007 Sep;8(3):241-53.

Taylor K, Vichova P, Hiscox S, Smart K, Hendley R, Nicholson RI (2007). Zinc-induced activation of EGFR in tamoxifen-resistant breast cancer cells is Src-dependant and mediated by zinc transporter HKE4/ZIP7. Endocrinology. 2008 Jun 26. [Epub ahead of print]

IR Hutcheson1, JM Knowlden, SE Hiscox, D Barrow, JMW Gee, JF Robertson, AlE Wakeling and RI Nicholson (2007). Heregulin ÿ1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells Breast Cancer Res. 2007;9(4):R50.

Hiscox S, Morgan L, Jordan N, Green TP and Nicholson RI. (2007). Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen resistant breast cancer cells. Clin Exp Met. 2007;24(3):157-67. Epub 2007 Mar 30

Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C and Nicholson RI (2006). Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Rel Cancer. 13(4):1085-1099.

Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. (2006). Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer. 13 Suppl 1:S77-88.

Hiscox S, Morgan L, Green TP and Nicholson RI. (2006). Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Rel Cancer. 13:53-59.

Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. (2006) Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of -catenin phosphorylation. Int J Cancer. 118:290-301.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM (2005). Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer.12:S29-36

Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM. (2005). Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol. 93:257-62

Hiscox S, Morgan L, Green T, Barrow D, Gee J, Nicholson RI. (2005). Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 97:263-274

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. (2004). Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res. 10:346S-354S

Jones HE., Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Williams S, Wakeling AE, Nicholson RI (2004). Insulin-like growth factor –1 receptor signalling and resistance to gefitinib (ZD1839; IRESSATM) in human breast and prostate cancer cells. Endocrine–Related Cancer, 1:793-814.

Taylor KM, Hiscox S, Nicholson RI. (2004) Zinc transporter LIV-1; A link between cellular development and cancer progression. Trends Endocrinology and Metabolism, 15:461-463

Jones HE, Nicholson RI, Hutcheson IR, Knowlden JM, Harper ME, Jordan NJ, Hiscox S, Gee JMW. (2004). Endocrine resistance in breast cancer: therapeutic intervention using signal transduction inhibitors. Adv Breast Can, Jan 2004, p1-4.

Hiscox S, Morgan L, Barrow D, Dutkowski C, Wakeling A, Nicholson RI. (2004). Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (‘Iressa’, ZD1839). Clin. Exp. Met 21: 201-212

Hiscox S, Hallett MB, Morgan BP, van den Berg CW. (2002). GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochem Biophys Res Commun. 293(2):714-721.

Stephens P, Hiscox S, Cook H, Jiang WG, Zhiquiang W, Thomas DW. (2001). Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts.Wound Repair Regen. 9(1):34-43

Books

Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their potential as Targets. Springer Publishing. Ed: Hiscox S, Gee J and Nicholson RI. 2008

Book chapters

Davies E, Hiscox S (2008). Modulation of cell-cell adhesive interactions by Src kinases: implications for tumour progression. In: New Cell Adhesion Research, Nova Science Publishers, Inc. Ed: Liman S Torres. In press

Hiscox S, Borley A, Nicholson RI and Barrett-Lee P. (2007). Epithelial-Mesenchymal Transition (EMT) and its involvement in endocrine resistance in breast cancer. In: Cancer Drug Resistance Research Perspectives, Nova Science Publishers, Inc. Ed: Liman S Torres. pp81-95

Hiscox S, Gee JM and Nicholson, RI. (2006). Endocrine resistance and breast cancer invasion, In: Metastasis of Breast Cancer,. Kluwer Publishers. Ed: W Jiang, O Foysted and RE Mansel. pp74-83

Hiscox S. (2000). Cancer and Cancer Metastasis related genes in ‘Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention’ Kluwer Academic Press. pp121-142.